Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ono Pharmaceutical has given additional marketing rights to Bristol-Myers Squibb (BMS) for developing and commercializing cancer drug, BMS-936558/ONO-4538.
Subscribe to our email newsletter
With this expanded deal, BMS has got the right to develop and commercialize BMS-936558/ONO-4538 in the rest of the world, except in Japan, Korea and Taiwan.
This agreement allows Ono to co-develop and co-commercialize Orencia (abatacept) in Japan with BMS.
The agreement covers both the currently approved intravenous (IV) formulation of Orencia and the subcutaneous (SC) formulation of Orencia, and includes all current and future indications.
Ono CEO, president and representative director Gyo Sagara said together with BMS they will be better able to quickly bring this potential new medicine to patients in need worldwide.